Literature DB >> 16581332

An assessment of statin safety by muscle experts.

Paul D Thompson1, Priscilla M Clarkson, Robert S Rosenson.   

Abstract

The National Lipid Association's (NLA) Muscle Safety Expert Panel was charged with the duty of examining the definitions, causative factors, and management of statin myopathy. The Panel was asked to use its evidence-based findings to form recommendations in response to a series of specific questions posed by the Task Force. The panel was composed of a clinical cardiologist, an exercise physiologist and skeletal muscle expert, and an expert in preventive cardiology who also examined skeletal muscle complications of statin use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16581332     DOI: 10.1016/j.amjcard.2005.12.013

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  73 in total

Review 1.  Drug-related myopathies of which the clinician should be aware.

Authors:  Ritu Valiyil; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

2.  Coenzyme Q(10) and statin myalgia: what is the evidence?

Authors:  Emilie Mas; Trevor A Mori
Journal:  Curr Atheroscler Rep       Date:  2010-11       Impact factor: 5.113

3.  Associations of Relative Handgrip Strength and Cardiovascular Disease Biomarkers in U.S. Adults, 2011-2012.

Authors:  Hannah G Lawman; Richard P Troiano; Frank M Perna; Chia-Yih Wang; Cheryl D Fryar; Cynthia L Ogden
Journal:  Am J Prev Med       Date:  2015-12-11       Impact factor: 5.043

4.  Fluvastatin-induced alterations of skeletal muscle function in hypercholesterolaemic rats.

Authors:  Márta Füzi; Zoltán Palicz; János Vincze; Julianna Cseri; Zita Szombathy; Ilona Kovács; Anna Oláh; Péter Szentesi; Pál Kertai; György Paragh; László Csernoch
Journal:  J Muscle Res Cell Motil       Date:  2011-11-09       Impact factor: 2.698

5.  Laparoscopic partial nephrectomy in a patient on simvastatin : Delayed recovery from neuromuscular blockade.

Authors:  E E Abd El-Hakeem; A M Kaki; S A Almazlom; A J Alsayyad
Journal:  Anaesthesist       Date:  2017-03-06       Impact factor: 1.041

Review 6.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Authors:  Russell A Wilke; Debbie W Lin; Dan M Roden; Paul B Watkins; David Flockhart; Issam Zineh; Kathleen M Giacomini; Ronald M Krauss
Journal:  Nat Rev Drug Discov       Date:  2007-11       Impact factor: 84.694

7.  Statin myopathy: incidence, risk factors, and pathophysiology.

Authors:  Kimberly A Sewright; Priscilla M Clarkson; Paul D Thompson
Journal:  Curr Atheroscler Rep       Date:  2007-11       Impact factor: 5.113

8.  The effect of statins on skeletal muscle function: the STOMP trial.

Authors:  John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2013-08       Impact factor: 5.113

9.  High-Content Assay Multiplexing for Muscle Toxicity Screening in Human-Induced Pluripotent Stem Cell-Derived Skeletal Myoblasts.

Authors:  William D Klaren; Ivan Rusyn
Journal:  Assay Drug Dev Technol       Date:  2018-08-02       Impact factor: 1.738

10.  Statin-associated polymyositis following omeprazole treatment.

Authors:  Rajan Kanth; Milind S Shah; Rafael Medina Flores
Journal:  Clin Med Res       Date:  2013-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.